Table of Contents
ISRN Endocrinology
Volume 2014 (2014), Article ID 816307, 8 pages
http://dx.doi.org/10.1155/2014/816307
Clinical Study

Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients

1Lycotec Ltd, Granta Park, Platinum Building, Cambridge CB21 6GP, UK
2Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt
3Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt
4Clinical Epidemiology and Biostatistics, Örebro University Hospital and School of Health and Medical Sciences, Örebro University, Örebro, Sweden

Received 1 August 2013; Accepted 9 October 2013; Published 20 February 2014

Academic Editors: T. Dinh and N. Tentolouris

Copyright © 2014 Yuriy K. Bashmakov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. The effect of a proprietary formulation of trans-resveratrol (t-RSV) on manifestations of diabetic foot syndrome (DFS) was studied in type 2 diabetic patients with newly diagnosed diabetic foot ulcers. Method. Placebo-controlled, examiner-blinded, parallel-group randomized controlled pilot clinical trial (ACTRN Clinical Trial Registry number 12610000629033) involving 24 patients with DFS (15 males and 9 females, average age of years) divided into the placebo and RSV-treatment groups was performed. 50 mg of t-RSV or placebo capsules was given to each patient twice a day over a 60-day time period. Results. Reduction in the parameters reflecting diabetic ulcer size was more profound in the RSV group as compared to placebo. RSV-treated patients also had a marginally improved performance in the foot pressure test. A statistically significant decline in the plasma fibrinogen level, but not CRP, was also found in the RSV-treated patients. Some improvement in the plasma lipid profile and fasting glucose levels were not related to RSV-treatment, since they have been seen on both the RSV and placebo groups, revealing the effectiveness of medical supervision and education in the newly diagnosed patients with DFS. Conclusion. t-RSV supplementation promotes reduction of the foot ulcer size and reduces plasma fibrinogen level in type 2 diabetic patients.